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Hypoxia and muscle maintenance regulation: implications for
chronic respiratory disease
Chiel de Theijea, Frédéric Costesb,c, Ramon C. Langend, Christophe Pisone,f,g,h
and Harry R. Goskerd
Introduction
Muscle wasting is a common but often under-recognized
extrapulmonary feature of chronic respiratory failure
(CRF) that significantly increases disease burden. Loss
of muscle mass can largely be attributed to muscle fibre
atrophy, particularly of type II fibres [1,2]. In addition to
the loss of muscle mass, peripheral muscles of patients
with chronic obstructive pulmonary disease (COPD)
often are characterized by a so-called loss of oxidative
phenotype (OXPHEN); a shift from slow oxidative type I
fibres towards fast glycolytic type II fibres, reduced
oxidative enzyme capacities and mitochondrial impair-
ments; for reviews, see [3,4]. In addition to increased
fatigability, loss of muscle OXPHEN may contribute to
elevated energy requirements (as oxidative energy
metabolism is more efficient than glycolytic energy
metabolism) and to enhanced oxidative stress, thereby
augmenting the onset or progression of muscle wasting
[5]. Hypoxemia, either chronic or intermittent, is an
obvious feature of respiratory failure, but surprisingly
its potential impact on muscle maintenance in CRF
patients is rather unexplored.
Molecular sensors of hypoxia
Probably, the most important regulators of cellular
responses to hypoxia belong to the hypoxia inducible
factor (HIF) family of transcription factors [6]. These
factors are heterodimeric proteins composed of a HIFa
(HIF1–3a, of which HIF1a is best described) and
a HIFb subunit. The HIFa gene is continuously
expressed, but under normoxic conditions, the protein
is rapidly hydroxylated by specific prolyl hydroxylases
(PHDs), enabling binding of the E3 ligase von Hippel-
Lindau (VHL) leading to degradation by the ubiquitin
proteasome pathway. As oxygen levels drop, so does the
rate of hydroxylation, thereby allowing for the build-up of
transcriptionally active HIF proteins, driving the expres-
sion of its target genes that are mainly involved in
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Purpose of review
Muscle wasting and impaired muscle oxidative metabolism are common extrapulmonary
features of chronic respiratory failure (CRF) that significantly increase disease burden.
This review aims to address the question whether hypoxia, an obvious consequence of
this disease, actually plays a causal role in these muscle impairments.
Recent findings
In experimental models, a causal role for hypoxia in muscle atrophy and metabolic
impairments has clearly been shown. Although the hypoxia-inducible factors and
nuclear factor kappa B are putative mediators of these hypoxia-induced alterations, their
true involvement remains to be proven. Molecular signatures of disrupted regulation of
muscle mass and oxidative metabolism observed in these experimental models also
have been shown in muscles of patients suffering from CRF, suggestive of but not
conclusive for a causal role of hypoxia. Therapies, including but not restricted to those
aimed at alleviating hypoxia, have been shown to partially but not completely restore
muscle mass and oxidative capacity in CRF patients, which may imply an additive effect
of nutritional modulation of substrate metabolism.
Summary
Although hypoxia clearly affects skeletal muscle maintenance, it remains to be confirmed
whether and by which underlying molecular mechanisms hypoxia is causally involved in
CRF-related muscle atrophy and impaired oxidative capacity.
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glycolytic metabolism and angiogenesis [6]. Evidence is
accumulating that the above mentioned PHDs can also
modulate nuclear factor kappa B (NF-kB) signalling
[7,8], indicative of hypoxia-signalling independent of
HIF1a. NF-kB is a family of proteins involved in innate
immunity, inflammation and apoptosis. Its upstream
regulation involves formation of an IkB kinase complex,
which through its kinase activity ultimately results in
NF-kB transcriptional activity [9]. Interestingly, evi-
dence for crosstalk between HIF1a and NF-kB is also
emerging [7,8]: although HIF1a is primarily post trans-
criptionally regulated, NF-kB has been reported to up-
regulate HIF1a gene expression and vice versa it has
been shown that HIF activates NF-kB signalling as well.
Given these facts, a primary regulatory role of the HIF
and NF-kB signalling pathways, orchestrated by the
PHDs, seems, therefore, credible in hypoxia-induced
alterations in muscle maintenance.
Hypoxia and maintenance of muscle mass
It is quite evident that hypoxia leads to muscle atrophy.
Observational studies in humans showed that long-term
exposure to high altitude resulted in loss of limb muscle
mass, which has been described as an adaptive mechan-
ism to improve muscle oxygenation by a relatively
increased capillarization [10,11]. Muscle atrophy also
occurs in animals exposed to experimental hypoxia
[12,13]. The balance between protein synthesis and
degradation is an important determinant of the mainten-
ance of skeletal muscle mass. Although most experimen-
tal work on hypoxia-induced protein turnover has thus far
focused on regulation of protein synthesis by hypoxia,
effects on ubiquitin (Ub) 26S-proteasome-mediated
protein degradation, as well as autophagy also have been
described (see Fig. 1 for a schematic overview). As most
of this work has been performed in nonmuscular cell
types and tissues, extrapolation of these results to skeletal
muscle protein turnover must be done with care.
Control of transcription can influence the rate of protein
synthesis and can be regulated by transcription factors.
HIFs are recognized as a key modulator of the transcrip-
tional response during hypoxic stress and are involved in
many adaptive responses including protein synthesis
[14]. The rate of mRNA translation is mainly controlled
during the initiation phase by eukaryotic translation
initiation factors (eIFs). eIF2a is permissive to mRNA
translation in the nonphosphorylated state, but blocks the
initiation of protein synthesis once it becomes phos-
phorylated by one of the four stress kinases which are,
among others, activated by hypoxia [15], oxidative and
endoplasmic reticulum stress [16]. Another eIF, eIF4E, is
inhibited when bound by eIF4E-binding protein 1
(4EBP1). Phosphorylation of 4EBP1 by the mammalian
target of rapamycin (mTOR) results in dissociation of
eIF4E from 4EBP1 and the formation of the translation-
initiation complex [17]. mTOR also activates ribosomal
protein S6 kinase beta-1 (P70S6K1), which in turn,
phosphorylates the ribosomal protein S6 (S6) and, thus,
stimulates translation. Hypoxia reduces phosphorylation
of mTOR and its downstream effectors 4EBP1 and
P70S6, and, thus, inhibits protein synthesis [18]. mTOR
phosphorylation itself is controlled by the tuberous
sclerosis protein 1 and 2 (TSC1/TSC2) complex, which
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Key points
 Maintenance of muscle mass and metabolism is
clearly affected by hypoxia.
 The molecular mechanisms through which chronic
hypoxia affects muscle maintenance are poorly
understood.
 A causal role for hypoxia in muscle atrophy and
impaired oxidative phenotype (OXPHEN) in
chronic respiratory failure is feasible, though
remains to be confirmed.
 Despite these uncertainties, therapies aimed at
alleviating hypoxemia or multimodal rehabilitation
strategies including nutritional modulation can, at
least partially, restore muscle mass and OXPHEN
in chronic respiratory failure.
Figure 1 Schematic overview of potential direct or indirect



























Hypoxia-inducible factor 1a (HIF1a), BCL2/adenovirus E1B 19 kDa
protein-interacting protein 3 (BNIP3), microtubule-associated protein 1
light chain-3 (LC3), eukaryotic translation initiation factor 2a (eIF2a), DNA-
damage-inducible transcript 4 protein (REDD1), tuberous sclerosis
protein 2 (TSC2), mammalian target of rapamycin (mTOR), eIF4E-binding
protein 1 (4EBP1), eukaryotic initiation factor 4E (eIF4E), ribosomal
protein S6 kinase beta-1 (P70S6K1), ribosomal protein S6 (S6), AMP-
activated protein kinase (AMPK), serine/threonine protein kinase AKT
(AKT), Myostatin (MSTN), Forkhead box O (FOXO), nuclear factor kappa
B (NF-kB), muscle atrophy F-box (Atrogin-1), muscle-specific ring finger 1
(MuRF1).
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is regulated by hypoxia-sensitive pathways, including
AMP-activated protein kinase (AMPK) and DNA-
damage-inducible transcript 4 protein (DDIT4/
REDD1). AMPK stimulates TSC2, which in turn inacti-
vates mTOR [19]. The degree of AMPK activation
depends on the severity of the hypoxic conditions [20].
Increased REDD1 expression during hypoxia results
from increased expression of the transcription factors
ATF4 and C/EBP-b. Hypoxia-induced expression of
ATF4 and C/EBP-b is a result of the development
of endoplasmatic reticulum stress and signalling via
eIF2a and does not seem to be dependent on HIF1a
[12,20,21]. Subsequent REDD1 expression results in
activation of TSC2, which subsequently inhibits mTOR
in response to hypoxia [22].
AKT is a serine/threonine protein kinase and a key
protein in the regulation of muscle mass, which controls
protein synthesis via mTOR, but also regulates protein
degradation. AKT activation by phosphoinositide
3-kinase (PI3K) is involved in the stimulation of myo-
genic differentiation by insulin growth factor-1 (IGF-1).
During hypoxia, this myogenic response changes into a
mitogenic response by redirection of IGF-1 signalling to
mitogen-activated protein kinase (MAPK) instead of
AKT activation. This finding implies that oxygen gradi-
ents may be of importance for myogenesis. It is currently
unknown by which mechanisms hypoxia influences AKT
phosphorylation, although HIF1a may play a role [14].
Increased protein degradation in skeletal muscle results
from increased lysosomal and/or proteasomal protein
degradation. Autophagy can be initiated in response to
nutritional depletion or hypoxia via activation of HIF1a
and/or endoplasmatic reticulum stress via BCL2/adeno-
virus E1B 19 kDa protein-interacting protein 3 (BNIP3)
and microtubule-associated protein 1 light chain-3 (LC3)
[23,24]. Autophagy, which captures organelles and
proteins in autophagic vacuoles, relies on lysosomal
protein degradation and is important in muscle mainten-
ance [25]. Muscle protein degradation is also controlled
by the ubiquitin-proteasome system (UPS). In this path-
way, the E3 Ub-ligases, muscle-specific ring finger 1
(MuRF1) and muscle atrophy F-box (Atrogin-1/MAFbx),
label muscle proteins with poly-ubiquitin (Ub) chains,
resulting in their targeted degradation by the 26S-protea-
some. The expression of both MuRF and Atrogin-1 are
increased during hypoxia [26,27]. The expression of
these atrogenes is regulated by inducible transcription
factors like NF-kB [28] and Forkhead box O (FOXO).
FOXO1 is negatively controlled by AKT-mediated phos-
phorylation, which results in its nuclear export and sub-
sequent suppression of the transcription of MuRF1 and
Atrogin-1 resulting in decreased protein degradation
[29,30]. However, the mechanisms by which hypoxia
controls expression of these atrogenes are still unclear.
The regulation of AKT activity may be the key in
regulating muscle mass during hypoxic conditions.
Myostatin (MSTN) signalling is able to suppress AKT
activation, which in turn decreases protein synthesis via
mTOR and derepression of FOXO1-mediated atrogenes
transcription [31,32]. MSTN expression is increased in
muscle atrophy during hypoxic conditions in humans, rats
and muscle cells [13]. Protein synthesis and degradation
are regulated by complex mechanisms, which allow rapid
adaptation to acute hypoxic stress. However, in response
to sustained hypoxic stress, adaptive mechanisms may
not be adequate in maintaining the balance in muscle
protein turnover, which may culminate in muscle atrophy
in chronic disease.
Hypoxia and maintenance of muscle
metabolism
Literature is rather inconsistent regarding the long-term
response of muscle metabolic profile to hypoxia and the
underlying molecular mechanisms remain unclear. The
adaptations of muscle in humans exposed to high altitude
have been extensively studied and the overall consensus
is that muscle adapts to high altitude hypoxia by a
decrease in oxidative capacity, whereas combined with
exercise training, muscle OXPHEN may even improve
[6,33,34]. In addition, numerous experiments have been
conducted in which rodents were exposed to chronic
hypoxia and in some of these studies, a relative loss of
muscle OXPHEN was indeed found, but not in others.
Although yet to be confirmed, it is possible that these
discrepancies were caused by differences in age as only
the younger animals seemed to exhibit loss of muscle
OXPHEN [35]. By using an in-vitro model in which
cultured muscle cells were exposed to low oxygen levels,
the mere effect of hypoxia could be studied, which
revealed a hypoxia-induced downregulation of the
expression of mitochondrial proteins [36]. The exact
mechanisms underlying hypoxia-induced loss of muscle
OXPHEN also remain largely unclear. There are a few
indications that point towards involvement of HIF1a,
which as mentioned earlier, indisputably is an important
enhancer of glycolytic metabolism, thus ‘away from’
oxidative metabolism. Muscles of patients with Chuvash
polycythemia, a disease with a genetic abnormality
resulting in an impaired HIF1a degradation resulting
in elevated HIF1a levels at normal oxygen tensions,
exhibited early and accelerated phosphocreatine
depletion accompanied by increased acidosis and lactate
accumulation during exercise, indicative of impaired
muscle OXPHEN [37]. Furthermore, higher mitochon-
drial enzyme activities have been observed in muscles of
mice lacking HIF1a [38]. Another potential way of
adjusting mitochondrial capacity to hypoxia is mitochon-
drial autophagy, which also requires HIF1a [39]. In rats,
HIF1a expression levels were found to be highest in the
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fast-twitch type II glycolytic muscles [40]. This study
furthermore showed elevated HIF1a levels in muscles
electrically stimulated with a high frequency (inducing
fast fibre type-specific genes) and reduced HIF1a levels
after low frequency stimulation (inducing slow fibre type-
specific genes), stressing the role of HIF1a in muscle
OXPHEN regulation even independent of hypoxia. It is,
however, unclear whether these results can be extrapo-
lated to humans, as HIF1a protein expression was found
not to be highest in glycolytic muscles but rather in
oxidative muscles [41]. The peroxisome proliferator-
activated receptors (PPARs) and in particular their co-
activator PGC1a are key regulators of OXPHEN in the
pre-existing and developing muscle [42,43]. In-vitro
studies showed that hypoxia can certainly impair com-
ponents of the PPAR pathway at transcriptional and post-
transcriptional level in cultured muscle cells [39], feasibly
leading to loss of muscle OXPHEN. Controversially,
PGC1a has been shown to induce the expression of
typical HIF1a target genes [especially those involved
in angiogenesis, like vascular endothelial growth factor
(VEGF)] at physiological oxygen levels [44]. A plausible
explanation for this apparent paradox might simply be the
fact that PGC1a-driven mitochondrial biogenesis leads to
an increased oxygen demand, which is not (yet) matched
by the oxygen supply and hence intracellular hypoxia
occurs triggering HIF1a-dependent gene expression
[45]. Alternatively, as NF-kB also has been implicated
in hypoxia-signalling, it can be speculated that NF-kB
also mediates hypoxia-induced loss of muscle OXPHEN.
Remels et al. [46] have recently shown that NF-kB
activation indeed impairs muscle OXPHEN, although
it remains to be established whether this also occurs
under hypoxia. Recapitulated, there are clear indications
that hypoxia can impair muscle OXPHEN, but it remains
to be clarified under what specific conditions and through
what mechanisms this really occurs.
Implications for chronic respiratory disease
Having discussed the (potential) mechanisms through
which hypoxia may impair muscle maintenance, what
indications do we actually have that hypoxia is involved
in muscle pathology in respiratory disease? The first
probably came from Jakobsson et al. [47] who reported
low percentages of type I fibres that were associated with
low arterial oxygen pressures in COPD. Impaired muscle
OXPHEN in COPD has been a consistent finding since
then, but strong evidence for the involvement of hypoxia
is lacking simply because this has not been further
studied in groups of patients with severe hypoxemia
(PaO2<7.3 kPa). In patients with restrictive lung disease
and mild hypoxemia related to scoliosis, Swallow et al.
[48] showed that impaired muscle function was associ-
ated with a decreased proportion of type I fibres and
increased oxidative stress. Pulmonary arterial hyperten-
sion is also an important cause of chronic hypoxemia and
skeletal muscle abnormalities have indeed been reported
in these patients as well, including decreased type I fibre
proportions and slightly reduced oxidative enzymes
[49]. As discussed above, the PPARs/PGC1a are key
OXPHEN regulators that may be under negative control
of hypoxia. Reduced expression levels of these regulators
have indeed been shown in muscles of patients with
COPD [50]. Regarding muscle atrophy, there are some
indications that in muscles of COPD patients, markers of
the ubiquitin proteasome pathway, including the atro-
genes MuRF1 and Atrogin-1, are increased [51,52].
Moreover, COPD exacerbations are frequently associ-
ated with augmented hypoxemia and fascinatingly, it has
recently been shown that the gene expression of these
atrogenes was upregulated, whereas OXPHEN expres-
sion was downregulated, in patients experiencing an
exacerbation as compared to stable COPD patients
[53]. Finally, increased expression levels of MSTN have
been reported for COPD patients characterized by hypox-
emia [13]. It is tempting to attribute all these findings to
hypoxemia, but a definitive conclusion is impossible. To
add to the ambiguity, the involvement of the putative
hypoxia sensors HIF and NF-kB in COPD-related muscle
pathology also remains distinct: muscle HIF gene expres-
sion tended to be increased in COPD, whereas the expres-
sion of the E3 ligase VHL, which targets HIFa for degra-
dation, was also increased [54]. Increased muscle NF-kB
activation has indeed been reported in COPD patients
with low body weight [55], although unaltered muscle NF-
kB activation has recently been observed in patients with
muscle atrophy [52]. The influence of chronic hypoxemia
was more specifically studied by Favier et al. [12] who
reported a downregulation of the anabolic AKT/mTOR
pathway and a tendency towards an upregulation of its
putative inhibitor REDD1 in hypoxemic versus normoxe-
mic patients with COPD.
In addition to the above mentioned direct effects of
hypoxia on muscle maintenance, indirect mechanisms
may also be involved in COPD. Loss of appetite and
subsequent cachexia is common in advanced COPD and
elevated circulating levels of leptin, a hormone that
indeed attenuates appetite and is induced by hypoxia
through HIF1a, have been reported for cachectic COPD
patients with more severe hypoxemia [56] and for COPD
patients suffering from an acute exacerbation [57]. Intri-
guingly, a correlation between the degree of hypoxemia
and circulating tumor necrosis factor (TNF-a) in patients
with COPD was observed as well [58], supportive of the
occurrence of hypoxia-induced systemic inflammation
[59], which in turn may contribute to muscle pathology
as well.
Additional arguments in favour of a role of hypoxia in
impaired muscle maintenance come from interventions
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aimed at alleviating hypoxemia. Jakobsson and Jorfeldt
[60] found signs of improved muscle oxidative metab-
olism after long-term oxygen therapy (LTOT). Lung
volume reduction surgery (LVRS) represents a functional
treatment for emphysema, which improves respiratory
mechanics and reduces dyspnea. Mineo et al. [61] showed
improvements in muscle mass that were maintained for at
least 5 years following LVRS and were associated with
improved outcomes. Interestingly, they also reported a
decrease in plasmatic inflammatory markers, such as
TNF-a, IL-6 and IL-8, 1 year after surgery [62], point-
ing towards the pre-existence of hypoxia-induced
systemic inflammation. After lung transplantation, thus
despite correction of hypoxemia, only partial restoration
of muscle OXPHEN has been reported, suggesting a
long-lasting signature of chronic hypoxia that could
partially be reversed by rehabilitation [63–65]. Indeed,
also therapies not (directly) aimed at alleviating hypox-
emia may prove beneficial, as for example recently shown
by improved muscle mass and performance in patients
with CRF and cachexia after multimodal nutritional
rehabilitation [66].
Conclusion
In experimental models, hypoxia evidently leads to
skeletal muscle atrophy and renders muscles less depen-
dent on oxidative energy metabolism. With respect to the
latter, it is, however, still questionable whether hypoxia
actually induces loss of muscle OXPHEN or merely
increases anaerobic capacity. Loss of muscle mass and
OXPHEN are evident in CRF and have been associated
with hypoxemia and although therapies aimed at alleviat-
ing hypoxemia have in fact been shown to partially
restore muscle mass and OXPHEN, a causal role for
hypoxia in the muscle impairments in CRF remains to
be verified. Moreover, alternative therapies, including
nutritional modulation, offer perspectives on improve-
ment of muscle maintenance in CRF.
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